Bartlomiejczyk, MA, Penson, P and Banach, M (2019) Worldwide Dyslipidemia Guidelines. Current Cardiovascular Risk Reports, 13 (2). ISSN 1932-9520

Full text not available from this repository. Please see publisher or open access link below:

Abstract

Purpose of review: This review aims to identify common features of guidelines by comparing and summarizing similarities between five guidelines distributed by high-profile cardiovascular societies across the globe. We include guidelines from North America: ACC/AHA (2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults); CCS (2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. From Europe: PoLA (2016 Polish Lipid Association), ESC/EAS (2016 European Society for Cardiology/European Atherosclerosis Society Guidelines for the Management of Dyslipidemias) and NICE (National Institute for Health and Care Excellence) from the U.K. We also include the 2016 Chinese guidelines for the management of dyslipidemia in adults in this comparison. Recent Findings: All of these guidelines employ a rigorous review of clinical evidence, and emphasize the immense importance of statins in the primary and secondary prevention of atherosclerotic cardiovascular disease. Moreover, they place great emphasis on the dialogue between the clinician and the patient regarding treatment and the risks associated with it. Summary: Despite the differences in statin intensities, safety concerns, use of risk estimators or treatment of specific patient subgroups; there are more similarities than differences between the guidelines from both a clinical and practical point of view. Physicians ought to understand both similarities and differences in guideline recommendations to make the right decision regarding statin therapy for individual patients.

Item Type:	Article
Additional Information:	This is a post-peer-review, pre-copyedit version of an article published in Current Cardiovascular Risk Reports. The final authenticated version is available online at: http://dx.doi.org/10.1007/s12170-019-0597-x
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Divisions:	Pharmacy & Biomolecular Sciences
Publisher:	Springer (part of Springer Nature)
Date Deposited:	09 Nov 2018 10:50
Last Modified:	03 Sep 2021 23:39
DOI or ID number:	10.1007/s12170-019-0597-x
URI:	https://researchonline.ljmu.ac.uk/id/eprint/9632

View Item